Michael J Fox Foundation raises $1m on #GivingTuesday

News

Author: Parkinson's Life editorsPublished: 7 December 2017

Prep: Cook: Serves:

The Michael J Fox Foundation for Parkinson’s Research raised $1 million on #GivingTuesday – 28 November – as part of their #1Day1million fundraising campaign.

The charity had pledged to match-fund any donation up to the one million dollar mark, with 89 cents from every dollar spent at The Foundation going directly to research programmes.

In a statement, the organisation said: “We did it: thanks to your support and energy, we met our Giving Tuesday goal of raising $1 million in one day, to help speed a cure for Parkinson’s disease.

“Thousands of friends and followers shared their dedication to fuelling Parkinson’s research, championed our mission online, and most critically, donated. It was incredible to see the outpouring of support for Parkinson’s community, demonstrating how together, we can – and we will – cure Parkinson’s disease.”

Last Month

Next Month

Go Back

Share this story

Comments

Advances

How a biobank could help solve Parkinson’s disease “puzzle”

Find out about a biobank in Sweden that’s helping to drive research

Watch: an animated story of Parkinson’s

Student Joshua-Gilroy Rossi discusses his Parkinson’s animation

A musical exploring young onset Parkinson’s

Writer Julie Walker shares her top tips for people living with young onset

35 new Parkinson’s drug trials launched in last year

Researchers launched 35 new clinical trials of Parkinson’s drug therapies in the last year, according to recent findings published in the ‘Journal of Parkinson’s Disease’. The 2023 Parkinson’s drug development pipeline report noted a slight decrease in active trials compared to the 2022 update (down from 147 to 139 overall). About one-third of trials were still in Phase 1, half were in Phase 2 – and just 20 (14%) were in Phase 3, raising concerns about ‘slow progress’. However, of the active trials logged on ClinicalTrials.gov at the time of the latest report, 35 were found to be newly registered. The report authors concluded: “The slow progress and lack of agents transitioning from Phase 2 to Phase 3 is concerning, but collective efforts by various stakeholders are being made to accelerate the clinical trial process, with the aim of bringing new therapies to the [Parkinson’s] community sooner.”

Parkinson’s Europe co-founder Lizzie Graham wins World Parkinson Coalition award

Parkinson’s Europe co-founder Lizzie Graham has won a World Parkinson Coalition (WPC) award for her contribution to the Parkinson’s community. Lizzie is one of four people set to receive the Robin Elliott Award – which is given out every three years to individuals whose efforts best embody the goals and ethos of the WPC. She will be presented with the award in a ceremony at the World Parkinson’s Congress, which will be held in Barcelona later this year. Commenting on the news of Lizzie’s award, Parkinson’s Europe President, Veronica Clark, said: “Lizzie is Lizzie, and we love her for who she is and what she has done for us all – for people with Parkinson’s past and present and, I’m sure, future.” Lizzie co-founded the European Parkinson’s Disease Association (renamed Parkinson’s Europe last year) in 1992. She has since held several roles within the organisation – including secretary general and…

Study explores predictors of cognitive impairment in Parkinson’s disease

Cognitive impairment can affect some people with Parkinson’s – and may greatly impact their quality of life. Now, researchers in China have examined the possible risk factors for cognitive impairment in those with the condition. The study analysed data from 409 people with Parkinson’s within two years of their involvement in the Parkinson’s Progression Markers Initiative (PPMI) – an international study that follows people with and without the condition over time. The participants, who were newly diagnosed and experiencing normal cognitive function at the start of the research, were studied for at least five years. Published in ‘Frontiers in Aging Neuroscience’, the results indicate that older age at onset, high blood pressure and worse baseline motor symptoms may be among factors that could contribute to an increased risk of developing cognitive impairment. The researchers cautioned that “a larger sample and much more comprehensive assessment, and prolonged follow-up, will be required”.

All fields required

First name*
Last name*
Email address*
Enter Email Confirm Email
Country of residence*
About me*
- I have Parkinson's disease
- I am a partner / carer / family / friend of someone who has Parkinson's
- I am a healthcare professional with an interest in Parkinson's
- I work for a Parkinson's disease organisation
- Other
CAPTCHA
*
- By proceeding you agree to our
Name
This field is for validation purposes and should be left unchanged.

Michael J Fox Foundation raises $1m on #GivingTuesday

News

Author: Parkinson's Life editorsPublished: 7 December 2017

Prep: Cook: Serves:

Last Month

Next Month

Share this story

Comments

Advances

How a biobank could help solve Parkinson’s disease “puzzle”

Interviews

Watch: an animated story of Parkinson’s

Interviews

A musical exploring young onset Parkinson’s

35 new Parkinson’s drug trials launched in last year

Parkinson’s Europe co-founder Lizzie Graham wins World Parkinson Coalition award

Study explores predictors of cognitive impairment in Parkinson’s disease

{title}

Subscribe

Michael J Fox Foundation raises $1m on #GivingTuesday

News

Author: Parkinson's Life editorsPublished: 7 December 2017

Last Month

Next Month

Share this story

Comments

Related articles

Advances

How a biobank could help solve Parkinson’s disease “puzzle”

Interviews

Watch: an animated story of Parkinson’s

Interviews

A musical exploring young onset Parkinson’s

35 new Parkinson’s drug trials launched in last year

Parkinson’s Europe co-founder Lizzie Graham wins World Parkinson Coalition award

Study explores predictors of cognitive impairment in Parkinson’s disease

{title}

Subscribe

Sign in